Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Published human trials mainly studied oral and intravenous forms, so subcutaneous amounts come from community practice rather than an approved clinical protocol
Despite these side effects, the overall safety profile of retatrutide remains favorable, with additional Phase III trials needed to further evaluate its long-term effects and any potential adverse events
Subcutaneous planning from a 50 mg vial reconstituted with 3.0 mL BAC water (~16.7 mg/mL) Phase Days 12 (tolerance) Daily dose 2.5 mg once daily Units on U-100 syringe 15 units Volume 0.15 mL Phase Days 3+ (standard) Daily dose 5 mg once daily Units on U-100 syringe 30 units Volume 0.30 mL Phase Split option (BID) Daily dose 2.5 mg twice daily Units on U-100 syringe 15 units each Volume 0.15 mL each These subcutaneous examples come from informal research discussions
04 Review at week 12 Decide whether the research question has been answered
US$ 25.58
US$ 24.18
US$ 29.41
US$ 29.43
US$ 20.94
